ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Oncology and Hematology News and Journal Articles

Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise

Phillip L. Palmbos, MD, PhD, and Maha H. Hussain, MD
This article will review how PARP inhibitors function as a class, review the molecular features that sensitize cancer cells to this therapy, and discuss the data supporting its potential for patients with prostate cancer.

Recent Content

Adding total body irradiation to chemotherapy prior to the adoptive cell transfer of TILs had no effect on tumor regression in patients with metastatic melanoma.

A 43-year-old woman is found to have a small tumor in her left fallopian tube, and a biopsy is performed. What is your diagnosis?

A 35-year-old HIV-positive man presents with enlarged lymph nodes, and a biopsy is performed. What is your diagnosis?

A new study has identified several trends by race and ethnicity among patients with hepatocellular carcinoma (HCC) in the United States.

The accuracy of interpreting a breast cancer screening mammogram is not diminished as clinicians get toward the end of a session.

A 5-year analysis of the DASISION trial showed that dasatinib continued to offer better responses than imatinib in patients with chronic myeloid leukemia.

Gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemotherapy-induced premature ovarian failure in young women with lymphoma.

By clicking Accept, you agree to become a member of the UBM Medica Community.